A securities class action has been filed in the USDC — N.J. against Novo Nordisk A/S. (NVO) (“Novo ” or the “Company”), on behalf of all persons or entities who purchased or otherwise acquired Novo common stock between November 2, 2022, and December 19, 2024, both dates inclusive (the “Class Period”).

Novo is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally. The Company operates in two segments, diabetes and obesity on one arm, and rare diseases on the other.

The complaint alleges that the Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s REDEFINE-1 trial protocol; notably, that it was a “flexible protocol” which gave patients the ability “to modify their dosing throughout the trial.” Such statements absent these material facts misled Plaintiff and other shareholders about the study’s risks and prospects for success and, in turn, caused them to purchase Novo’s securities at artificially inflated prices.

After the announcement of the results for REDEFINE-1 trial, the price of Novo’s common stock declined dramatically to $85.00 per share on December 20, 2024.

If you purchased Novo common stock during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.